References
- Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic– pharmacodynamic relationships be helpful in addresssing the issue of appropriate pneumonia treatment in critically ill patients? Clin. Infect. Dis.42, 1764–1771 (2006).
- Craig WA. Pharmacokinetic/pharmacodinamic parameters: rationale for antibiotic dosing of mice and men. Clin. Infect. Dis.26, 1–10 (1998).
- Mueller M, de la Peña A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother.48, 369–377 (2004).
- Lodise TP, Lomaestro B, Drusano GL. Piperacillin–tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis.44, 357–363 (2007).
- Sanchez-Navarro A, Sanchez Recio MM. Basis of anti-infective therapy: pharmacokinetic – pharmacodynamic criteria and methodology for dual dosage individualisation. Clin. Pharmacokinet.37, 289–304 (1999).
- Astigarraga PM, Montero J, Grau-Cerrato S et al. GEIPC-SEIMC and [GTEI-SEMICYUC recommendations for antibiotic treatment of Gram positive coccal infections in the critical patient]. Enferm. Infecc. Microbiol. Clin.25, 446–466 (2007).
- Zahar JR, Rioux C, Girou E et al. Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. J. Antimicrob. Chemother.58, 651–656 (2006).
- Bakker-Woudenberg IAJM, ten Kate MT, Goessens WHF, Mouton JW. Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumonia lung infection. Antimicrob. Agents Chemother.50, 2919–2925 (2006).
- Burton ME, Shaw LM, Schentang JJ, Evans WE. Applied Pharmacokinetics Pharmacodynamics. Principles of Therapeutic Drug Monitoring. Lippincott Williams & Wilkins, MD, USA (2006).
Website
- Department of Health and Human Services US FDA guidance for industry: bioanalytical method validation USA www.fda.gov/cder/guidance/4252fnl.pdf